Top-line outcomes at the 48-week primary endpoint, by dose: Secondary endpoint magnitudes at the 12mg cohort: approximately 41% mean reduction in fasting insulin
Can you guess who our first patient was
Contact your GP, trial coordinator, or a healthcare professional promptly but without the urgency of 999 if you experience: A widespread or rapidly spreading rash, particularly if accompanied by fever, joint pain, or malaise Blistering, peeling, or open sores on the skin, which may indicate a more serious dermatological reaction Persistent or worsening injection site reactions that do not resolve within a few days Skin changes accompanied by systemic symptoms such as fatigue, fever, or lymph node swelling Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome or toxic epidermal necrolysis, are rare but serious drug-related skin conditions requiring emergency assessment
10.1071/RD15336 62
However, c-20:1 FAs exhibited less effect than c-18:1 and c-22:1 [185]
.webp)
